Journal Article Summary
The article investigates the prescribing trends and long-term effectiveness of two formulations of indapamide, a diuretic used to treat hypertension: modified release and immediate release. This topic is important because indapamide is commonly prescribed for managing high blood pressure, and understanding the differences in effectiveness between these formulations can help inform treatment decisions. The study aims to clarify whether one formulation is more beneficial than the other in preventing cardiovascular events and mortality, which are critical concerns for patients with hypertension.
The researchers conducted a cohort study using data from the IQVIA Medical Research Data UK database, analyzing records from over 1.9 million patients diagnosed with hypertension between 2005 and 2020. Among these, 86,388 patients started treatment with indapamide, with 30,021 receiving modified release and 56,367 receiving immediate release. The findings indicated that while the use of immediate release indapamide increased significantly over the years, the risks of cardiovascular events and death were similar for both formulations when treatment was initiated. However, in a secondary analysis, patients who consistently used modified release indapamide showed a lower risk of cardiovascular events compared to those on immediate release, although there was no difference in overall mortality.
Despite the valuable insights provided, the study has limitations that should be considered. For instance, it relied on prescription records, which may not accurately reflect actual medication adherence, potentially leading to misclassification of treatment effects. Additionally, the study did not capture all cardiovascular events, as it only included data from primary care settings. Patients and caregivers should discuss these findings with healthcare professionals, considering factors such as adherence, side effects, and personal health circumstances when choosing between modified release and immediate release indapamide for hypertension management.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Yan Vincent Ka Chun, Ju Chengsheng, MacDonald Thomas MacLennan, Mackenzie Isla S, Flynn Robert, Williams Bryan, Chen Yang, Chan Esther W, et al.. Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study. BMJ Medicine 2025. DOI: 10.1136/bmjmed-2024-000857. PMID: 40551877. PMCID: PMC12184341.
Featured Pill Pals Product
Indapamide 1.25 mg Tablets --- Generic For Lozol --- ANI Pharma
Indapamide 1.25 mg Tablets — Generic For Lozol — ANI Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
